Answer
Yes, octocog alfa replacement therapy may increase cardiovascular risk in patients with existing cardiovascular risk factors.
Sources for this answer
- ADVATE 250 IU, 500 IU,1000 IU, 1500 IU, 2000 IU and 3000 IU powder and solvent for solution for injection 5 ml solventTakeda UK Ltd · emc · SmPC §4.4 Special warnings and precautions for use · Version 14Document updated
Sources checked